TY - JOUR
T1 - Priorities for sexually transmitted infection vaccine research and development
T2 - Results from a survey of global leaders and representatives
AU - Plotnikoff, Kara M
AU - Donken, Robine
AU - Smith, Laurie
AU - Cameron, Caroline
AU - LaMontagne, D Scott
AU - Bettinger, Julie A
AU - Sadarangani, Manish
AU - Grennan, Troy
AU - Racey, C Sarai
AU - Hybiske, Kevin
AU - Naus, Monika
AU - Monteiro, Amanda
AU - Ogilvie, Gina S
N1 - Funding Information:
We would like to thank the STI & HIV 2019 World Congress for the time and space to host this symposium, and for allowing the survey to be distributed. Additional thanks to the symposium attendees for completing this survey. GO conceived the study. All authors provided feedback on the survey used. KP and AM prepared the surveys for administration and data collection. KP and RD performed the data analysis. KP wrote the first draft of the manuscript. All authors provided critical revisions. The University of British Columbia has provided operating funds for the STRIVEBC consortium. STRIVEBC received a Institute Community Support grant from CIHR Institute for Infection and Immunity to host the STI Vaccines symposium. CIHR was not involved in the design, data collection, or analysis of this work.
Funding Information:
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: GO, LWS, RD, CC, JAB, MS, CSR, TG, MN are members of the STRIVEBC consortium. The core team who completed the data analysis and interpretation of results (KP, RD, LS, GO) did not complete the survey. MS is supported via salary awards from the BC Children’s Hospital Foundation, the Canadian Child Health Clinician Scientist Program and the Michael Smith Foundation for Health Research. MS has been an investigator on projects funded by Pfizer, Merck, VBI Vaccines, Seqirus, Sanofi-Pasteur and GlaxoSmithKline. All funds have been paid to his institute, and he has not received any personal payments. RD has received fellowships from the Canadian Immunization Research Network and Michael Smith Foundation for Health Research. CSR received a fellowship from Michael Smith Foundation for Health Research. All other authors have no competing interests.
Publisher Copyright:
© 2021
PY - 2021/8
Y1 - 2021/8
N2 - Objective: To determine the sexually transmitted infection (STI) vaccine research priorities of global leaders in STI vaccine research, development, and service provision.Methods: Global representatives attending the STI Vaccines: Opportunities for Research, Development, and Implementation symposium preceding the STI & HIV World Congress in 2019 were invited to complete an electronic survey. We asked participants to rank items by importance/priority for STI vaccine development for the following areas of focus: specific STIs (gonorrhea, chlamydia, syphilis, herpes, and trichomoniasis), broad research domains (basic science, funding, communication, program planning, and vaccine hesitancy), and specific research activities related to these domains. We calculated weighted value scores based on the ranking (e.g., first, second, third) and the total number of responses in order to produce a ranked list of the priorities.Results: A total of 46 out of 97 (44%) symposium attendees responded to the survey. Gonorrhea was identified as the STI that should be prioritized for vaccine development, followed by syphilis with weighted value scores of 3.82 and 3.37, respectively, out of a maximum of five. Basic science (and vaccine development) was the domain ranked with the highest priority with a weighted value score of 4.78 out of six. Research activities related to basic science and vaccine development (including pre-clinical and clinical trials, and surveillance measures) and increased funding opportunities were the most highly ranked activities in the "STI vaccine development" and "research domains and activities" categories.Conclusion: Global leaders in attendance at the STI Vaccines symposium prioritized continued scientific work in vaccine development and program planning. Gonorrhea was identified as the highest priority infection, followed by syphilis.
AB - Objective: To determine the sexually transmitted infection (STI) vaccine research priorities of global leaders in STI vaccine research, development, and service provision.Methods: Global representatives attending the STI Vaccines: Opportunities for Research, Development, and Implementation symposium preceding the STI & HIV World Congress in 2019 were invited to complete an electronic survey. We asked participants to rank items by importance/priority for STI vaccine development for the following areas of focus: specific STIs (gonorrhea, chlamydia, syphilis, herpes, and trichomoniasis), broad research domains (basic science, funding, communication, program planning, and vaccine hesitancy), and specific research activities related to these domains. We calculated weighted value scores based on the ranking (e.g., first, second, third) and the total number of responses in order to produce a ranked list of the priorities.Results: A total of 46 out of 97 (44%) symposium attendees responded to the survey. Gonorrhea was identified as the STI that should be prioritized for vaccine development, followed by syphilis with weighted value scores of 3.82 and 3.37, respectively, out of a maximum of five. Basic science (and vaccine development) was the domain ranked with the highest priority with a weighted value score of 4.78 out of six. Research activities related to basic science and vaccine development (including pre-clinical and clinical trials, and surveillance measures) and increased funding opportunities were the most highly ranked activities in the "STI vaccine development" and "research domains and activities" categories.Conclusion: Global leaders in attendance at the STI Vaccines symposium prioritized continued scientific work in vaccine development and program planning. Gonorrhea was identified as the highest priority infection, followed by syphilis.
KW - Prevention
KW - Priorities
KW - Public health
KW - Sexually transmitted infections
KW - Vaccines
UR - http://www.scopus.com/inward/record.url?scp=85110241360&partnerID=8YFLogxK
U2 - 10.1016/j.jvacx.2021.100107
DO - 10.1016/j.jvacx.2021.100107
M3 - Article
C2 - 34401741
SN - 2590-1362
VL - 8
SP - 100107
JO - Vaccine: X
JF - Vaccine: X
M1 - 100107
ER -